<DOC>
	<DOCNO>NCT00002587</DOCNO>
	<brief_summary>Phase I trial study effectiveness paclitaxel plus topotecan treating patient solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Paclitaxel Plus Topotecan Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose quantitative qualitative toxic effect topotecan paclitaxel patient solid tumor . II . Determine antitumor activity regimen patient . OUTLINE : This dose escalation study topotecan paclitaxel . Patients receive paclitaxel IV 3 hour day 1 follow 2-6 hour later topotecan IV continuously day 1-14 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos topotecan paclitaxel maximum tolerate dose ( MTD ) drug determine . The MTD define high dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 10-20 patient accrue study within 8-12 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor Measurable evaluable disease Measurable disease define tumor outside prior radiotherapy field reproducibly measurable 2 dimension physical exam , xray , CT , MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : 0 1 Life expectancy : At least 12 week WBC least 4,000/mm3 Platelet count least 100,000/mm3 Bilirubin great 1.5 mg/dL AST le 3 time normal Alkaline phosphatase less 3 time normal Creatinine great 1.5 mg/dL No poorly control angina No history congestive heart failure No myocardial infarction within past 6 month Not pregnant nursing PRIOR CONCURRENT THERAPY : No concurrent prophylactic hematopoietic growth factor No concurrent medication alter cardiac conduction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>